Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
$128.15
-0.1%
$108.40
$73.04
$128.45
$8.28B0.841.29 million shs2.53 million shs
Bavarian Nordic stock logo
BVNRY
Bavarian Nordic
$8.72
-0.7%
$8.45
$6.60
$14.60
$2.06B1.363,864 shs1,252 shs
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$11.60
+1.8%
$11.08
$8.73
$13.06
$7.75B1.165.64 million shs6.02 million shs
Bio-Techne Corp stock logo
TECH
Bio-Techne
$52.80
+1.8%
$49.56
$46.01
$83.62
$8.13B1.381.45 million shs2.35 million shs
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
-0.08%+0.02%+28.07%+44.44%+23.32%
Bavarian Nordic stock logo
BVNRY
Bavarian Nordic
0.00%-3.02%+0.26%+14.29%-0.23%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
+1.75%+1.40%+7.81%+11.75%+9.74%
Bio-Techne Corp stock logo
TECH
Bio-Techne
+1.76%+5.33%+8.44%-10.10%-26.77%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
1.0371 of 5 stars
2.12.00.00.02.20.80.6
Bavarian Nordic stock logo
BVNRY
Bavarian Nordic
N/AN/AN/AN/AN/AN/AN/AN/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
2.6058 of 5 stars
3.53.00.00.02.62.50.0
Bio-Techne Corp stock logo
TECH
Bio-Techne
4.8655 of 5 stars
4.23.01.74.22.21.71.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
2.27
Hold$128.06-0.07% Downside
Bavarian Nordic stock logo
BVNRY
Bavarian Nordic
0.00
N/AN/AN/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
3.00
Buy$17.5050.86% Upside
Bio-Techne Corp stock logo
TECH
Bio-Techne
2.45
Hold$72.0036.36% Upside

Current Analyst Ratings Breakdown

Latest BVNRY, BPMC, TECH, and ROIV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/18/2025
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$18.00
6/17/2025
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold$143.00 ➝ $129.00
6/5/2025
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$102.00 ➝ $129.00
6/5/2025
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$88.00 ➝ $129.00
6/5/2025
Bio-Techne Corp stock logo
TECH
Bio-Techne
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$75.00
6/4/2025
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong Sell ➝ Hold$83.00 ➝ $129.00
6/3/2025
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$132.00
6/3/2025
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
6/3/2025
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
6/3/2025
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
Citizens Jmp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
6/3/2025
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Perform
(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
$508.82M16.26N/AN/A$4.70 per share27.27
Bavarian Nordic stock logo
BVNRY
Bavarian Nordic
$829.12M2.49$1.01 per share8.61$6.99 per share1.25
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$29.05M271.46N/AN/A$7.45 per share1.56
Bio-Techne Corp stock logo
TECH
Bio-Techne
$1.16B7.14$2.36 per share22.42$13.13 per share4.02
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
-$67.09M-$2.47N/A197.15N/A-27.70%-64.60%-17.22%7/30/2025 (Estimated)
Bavarian Nordic stock logo
BVNRY
Bavarian Nordic
$143.26M$0.8010.908.30N/A21.11%11.89%9.32%8/22/2025 (Estimated)
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-$171.98M-$0.25N/AN/AN/A-225.71%-14.76%-13.69%8/6/2025 (Estimated)
Bio-Techne Corp stock logo
TECH
Bio-Techne
$168.10M$0.8264.3926.802.7410.89%13.17%10.17%8/6/2025 (Estimated)

Latest BVNRY, BPMC, TECH, and ROIV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/29/2025Q4 2025
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-$0.16-$0.31-$0.15-$0.29$62.17 million$7.57 million
5/9/2025Q1 2025
Bavarian Nordic stock logo
BVNRY
Bavarian Nordic
N/A$0.13N/A$0.13N/A$189.89 million
5/7/2025Q3 2025
Bio-Techne Corp stock logo
TECH
Bio-Techne
$0.51$0.56+$0.05$0.14$317.92 million$316.18 million
5/1/2025Q1 2025
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
-$0.42-$0.74-$0.32$0.01$158.31 million$149.41 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
N/AN/AN/AN/AN/A
Bavarian Nordic stock logo
BVNRY
Bavarian Nordic
N/AN/AN/AN/AN/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
N/AN/AN/AN/AN/A
Bio-Techne Corp stock logo
TECH
Bio-Techne
$0.320.61%N/A39.02%N/A

Latest BVNRY, BPMC, TECH, and ROIV Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/19/2025
Bio-Techne Corp stock logo
TECH
Bio-Techne
quarterly$0.080.67%5/19/20255/19/20255/30/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
1.01
2.80
2.75
Bavarian Nordic stock logo
BVNRY
Bavarian Nordic
N/A
2.81
1.44
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
N/A
33.47
33.47
Bio-Techne Corp stock logo
TECH
Bio-Techne
0.16
3.71
2.58

Institutional Ownership

CompanyInstitutional Ownership
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
N/A
Bavarian Nordic stock logo
BVNRY
Bavarian Nordic
N/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
64.76%
Bio-Techne Corp stock logo
TECH
Bio-Techne
98.95%

Insider Ownership

CompanyInsider Ownership
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
4.21%
Bavarian Nordic stock logo
BVNRY
Bavarian Nordic
N/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
7.90%
Bio-Techne Corp stock logo
TECH
Bio-Techne
3.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
64064.58 million61.86 millionOptionable
Bavarian Nordic stock logo
BVNRY
Bavarian Nordic
1,611236.57 millionN/ANot Optionable
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
860679.81 million626.10 millionOptionable
Bio-Techne Corp stock logo
TECH
Bio-Techne
3,100156.77 million150.65 millionOptionable

Recent News About These Companies

Is Bio-Techne Stock Underperforming the Nasdaq?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Blueprint Medicines stock logo

Blueprint Medicines NASDAQ:BPMC

$128.15 -0.10 (-0.08%)
Closing price 06/26/2025 04:00 PM Eastern
Extended Trading
$128.06 -0.09 (-0.07%)
As of 04:09 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Bavarian Nordic stock logo

Bavarian Nordic OTCMKTS:BVNRY

$8.72 -0.06 (-0.68%)
As of 06/25/2025 03:15 PM Eastern

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase III clinical trial for the treatment of SARS-CoV-2. The company has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. It operates in the United States, Canada, France, Germany, Spain, Australia, Switzerland, Sweden, Chile, Taiwan, the United Kingdom, Hong Kong, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.

Roivant Sciences stock logo

Roivant Sciences NASDAQ:ROIV

$11.60 +0.20 (+1.75%)
Closing price 06/26/2025 04:00 PM Eastern
Extended Trading
$11.60 0.00 (-0.04%)
As of 06/26/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

Bio-Techne stock logo

Bio-Techne NASDAQ:TECH

$52.80 +0.91 (+1.75%)
Closing price 06/26/2025 04:00 PM Eastern
Extended Trading
$52.94 +0.14 (+0.26%)
As of 06/26/2025 07:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.